Answers are grounded in this paper and cite their sources.
OSW-1, a natural compound with potent anticancer activity, has shown significant therapeutic potential in colorectal cancer (CRC). Although previous studies have implicated necroptosis, the upstream regulatory mechanisms linking autophagy to necroptosis remain incompletely defined. In this study, we systematically investigated the anticancer mechanisms of OSW-1 in CRC cells, with a particular focus on its ability to induce necroptosis via modulation of autophagic flux. The results demonstrate that OSW-1 activates AMPK (AMP-activated protein kinase) and inhibits mTORC1 (mammalian target of rapamycin complex 1), thereby promoting the nuclear translocation of TFEB (transcription factor EB) and initiating autophagy as well as lysosome biogenesis. However, OSW-1 downregulates STX17 (syntaxin 17) via an AMPK-independent mechanism, thereby disrupting autophagosome-lysosome fusion, blocking autophagic flux and causing the accumulation of SQSTM1/p62, which in turn promotes RIPK1 (receptor-interacting protein kinase 1) and RIPK3-mediated necrosome assembly, ultimately leading to necroptosis. The AMPK inhibitor compound C (CC) partially restores autophagic flux and reduces necroptosis, confirming the pivotal role of the AMPK/mTORC1/TFEB pathway in mediating OSW-1’s effects. In vivo experiments further demonstrate that OSW-1 significantly inhibits the growth of CRC xenograft tumors. Following OSW-1 treatment, AMPK is activated, and SQSTM1/p62 accumulation induces necroptosis. This study is the first to comprehensively elucidate the molecular mechanisms by which OSW-1 exerts its anticancer effects through the “autophagic flux blockade-necroptosis” pathway, providing an important theoretical basis for its potential clinical application.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: